DK2312318T3 - Prion-proteinligander samt fremgangsmåder til anvendelse deraf - Google Patents
Prion-proteinligander samt fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2312318T3 DK2312318T3 DK10176708T DK10176708T DK2312318T3 DK 2312318 T3 DK2312318 T3 DK 2312318T3 DK 10176708 T DK10176708 T DK 10176708T DK 10176708 T DK10176708 T DK 10176708T DK 2312318 T3 DK2312318 T3 DK 2312318T3
- Authority
- DK
- Denmark
- Prior art keywords
- ligand
- prion
- ligands
- sample
- prion protein
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (14)
1. Prionbindende ligand, hvor liganden er et peptid, der består af aminosyresekvensen ifølge SEQ ID NO: 63.
2. Ligand ifølge krav 1, hvor liganden er i stand til at binde til en nativ form at prionprotein (PrPc) og/eller en konformationelt ændret form af prionprotein (PrPsc) .
3. Ligand ifølge enten krav 1 eller krav 2, hvor liganden har en molekylvægt på mindre end 6 kDa.
4. Ex vivo-fremgangsmåde til detektering af et prionprotein i en prøve, hvilken fremgangsmåde omfatter: etablering af kontakt mellem prøven og en ligand ifølge et hvilket som helst af kravene 1 til 3, der er i stand til at binde til et eller flere prionproteiner, et fragment deraf eller et peptid, der er afledt derfra, under betingelser, der er tilstrækkelige til at forårsage dannelse af et kompleks mellem prionproteinet, fragmentet deraf eller peptidet, der er afledt derfra, og liganden; og at detektere komplekset i prøven.
5. Ex vivo-fremgangsmåde til fjernelse af et prionprotein i en prøve, hvilken fremgangsmåde omfatter: etablering af kontakt mellem prøven og en ligand ifølge et hvilket som helst af kravene 1 til 3, der er i stand til at binde til et eller flere peptider eller polypeptider, der er afledt fra et prionprotein, der er udvalgt fra gruppen, der består af PrPc, PrPsc og PrPr, under betingelser, der er tilstrækkelige til at forårsage dannelse af et kompleks mellem prionproteinet og liganden; og at fjerne komplekset fra prøven.
6. Fremgangsmåde ifølge enten krav 4 eller krav 5, hvorved prøven er en biologisk prøve.
7. Fremgangsmåde ifølge krav 6, hvorved den biologiske prøve er udvalgt fra gruppen bestående af fuldblod, hvide celler, mononukleare celler, blodpladekoncentrater, blod, plasma, serum, cerebrospinalvæske, urin, spyt, mælk, kanalfluidum, tårer, sæd, fæces, mandler, lymfeknuder, kollagen, hjerneekstrakter og kirtelekstrakter.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 4 til 7, hvorved liganden fastgøres til en faststofbærer inden kontakt med prøven.
9. Fremgangsmåde ifølge krav 8, hvorved faststofbæreren udvælges fra gruppen bestående af membraner og resiner.
10. Fremgangsmåde ifølge enten krav 8 eller krav 9, hvorved faststofbæreren er en resin, der er udvalgt fra gruppen bestående af polymethacrylat, agarose, sepharose, tværbunden agarose, kompositte tværbundne polysaccharider, celit, polyvinyl D, fluoridacrylat, polystyren og cellulose.
11. Fremgangsmåde ifølge enten krav 8 eller krav 9, hvorved faststofbæreren er polymethacrylatresin.
12. Fremgangsmåde ifølge enten krav 8 eller krav 9, hvor den faste understøtning er en membran af et materiale, der er udvalgt fra gruppen, der består af nylon og cellulose.
13. Sammensætning til binding af prionproteiner, der omfatter: en ligand ifølge et hvilket som helst af kravene 1 til 3, der er i stand til at binde til et eller flere prionpeptider; og et fast bæremateriale, hvor liganden bindes til det faste bæremateriale.
14. Sammensætning ifølge krav 13, hvor det faste bæremateriale er udvalgt fra gruppen, der består af membraner og resiner.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43042302P | 2002-12-03 | 2002-12-03 | |
| EP03808431A EP1573323B1 (en) | 2002-12-03 | 2003-12-03 | Prion protein ligands and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2312318T3 true DK2312318T3 (da) | 2015-01-12 |
Family
ID=32469468
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10176708T DK2312318T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| DK08150151T DK1953551T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| DK03808431.5T DK1573323T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| DK10176707T DK2317317T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08150151T DK1953551T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| DK03808431.5T DK1573323T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| DK10176707T DK2317317T3 (da) | 2002-12-03 | 2003-12-03 | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7863411B2 (da) |
| EP (4) | EP1573323B1 (da) |
| JP (1) | JP4485367B2 (da) |
| CN (3) | CN1739029B (da) |
| AT (1) | ATE529744T1 (da) |
| AU (2) | AU2003302500B2 (da) |
| CA (2) | CA2836951C (da) |
| DK (4) | DK2312318T3 (da) |
| ES (4) | ES2531926T3 (da) |
| HK (4) | HK1088948A1 (da) |
| IL (3) | IL168904A (da) |
| MX (2) | MXPA05005920A (da) |
| NZ (3) | NZ572892A (da) |
| PT (4) | PT1953551E (da) |
| WO (1) | WO2004050851A2 (da) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395833B1 (en) * | 2001-05-31 | 2013-02-27 | Adlyfe, Inc. | Misfolded protein sensor method |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| US7863411B2 (en) * | 2002-12-03 | 2011-01-04 | Pathogen Removal and Diagnostics Technologies Inc. | Prion protein ligands and methods of use |
| CA2522483A1 (en) * | 2003-04-14 | 2004-10-28 | Julia T. Lathrop | Method for identifying ligands specific for structural isoforms of proteins |
| JP4709149B2 (ja) | 2003-08-13 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | プリオン特異的ペプチド試薬 |
| US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
| ATE528649T1 (de) * | 2005-02-15 | 2011-10-15 | Adlyfe Inc | Verfahren zum nachweis falsch gefalteter proteine und prionen |
| NZ566020A (en) * | 2005-09-09 | 2012-08-31 | Novartis Ag | Prion-specific peptoid reagents |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| DK1994155T4 (da) | 2006-02-13 | 2022-07-25 | Daiichi Sankyo Co Ltd | Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering |
| WO2008005960A2 (en) * | 2006-07-07 | 2008-01-10 | Pall Corporation | Prion processing |
| WO2008013859A2 (en) * | 2006-07-28 | 2008-01-31 | Adlyfe, Inc. | Peptide probes for diagnostics and therapeutics |
| CA2675039A1 (en) * | 2007-01-12 | 2008-07-17 | Alicon Ag | Method for removing prion protein |
| CN102083450A (zh) * | 2008-04-30 | 2011-06-01 | 诺华有限公司 | 致病性构象异构体的分析 |
| WO2010121000A1 (en) * | 2009-04-15 | 2010-10-21 | Abraxis Bioscience, Llc | Prion-free nanoparticle compositions and methods |
| AU2010250104B2 (en) * | 2009-05-21 | 2014-04-24 | American National Red Cross | Inhibition of prion protein propagation by receptor associated protein (RAP). its derivatives, mimetics and synthetic peptides |
| US8841429B2 (en) * | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| CA2779846A1 (en) * | 2009-11-04 | 2011-05-12 | Novartis Ag | Positively charged species as binding reagents in the separation of protein aggregates from monomers |
| US9162223B2 (en) | 2011-12-21 | 2015-10-20 | North Carolina State University | Alkaline-stable chromatographic resins |
| ES2723885T3 (es) | 2012-07-19 | 2019-09-03 | Daiichi Sankyo Co Ltd | Anticuerpos anti-Siglec-15 |
| CN103336124B (zh) * | 2012-12-11 | 2015-07-15 | 武汉工业学院 | 一种检测朊病毒蛋白(PrPSC)的方法和试剂盒 |
| EP2995621A1 (en) | 2014-09-10 | 2016-03-16 | Previpharma AG | Ligands and methods for isolating or removing proteins |
| RU2018107453A (ru) | 2015-08-10 | 2019-09-12 | Эссенликс Корп. | Устройства для анализов и способы в биологии/химии, предусматривающие упрощенные стадии, образцы небольшого объема, повышенную скорость и простоту применения |
| KR101982330B1 (ko) | 2015-09-14 | 2019-05-24 | 에센릭스 코프. | 증기 응축액 특히 입김 응축액을 수집 및 분석하기 위한 장치 및 시스템 그리고 이 장치 및 시스템을 사용하는 방법 |
| CN112462055B (zh) | 2015-09-14 | 2024-06-07 | 上海宜晟生物科技有限公司 | 用于分析样品，尤其是血液，的装置和系统以及其使用方法 |
| EP3558121B1 (en) | 2016-12-21 | 2022-06-08 | Essenlix Corporation | Devices and methods for authenticating a sample and use of the same |
| WO2018148342A1 (en) | 2017-02-07 | 2018-08-16 | Essenlix Corporation | Compressed open flow assay and use |
| US12066434B2 (en) | 2017-02-08 | 2024-08-20 | Essenlix Corporation | QMAX assays and applications |
| CA3053002A1 (en) | 2017-02-08 | 2018-08-16 | Essenlix Corp. | Bio/chemical material extraction and assay |
| CA3053005A1 (en) | 2017-02-08 | 2018-08-16 | Essenlix Corporation | Sample collection and handling for delayed analysis |
| CN111433606B (zh) | 2017-02-09 | 2024-05-24 | 上海宜晟生物科技有限公司 | 采用不同间距高度的测定 |
| EP3662259A4 (en) | 2017-02-09 | 2021-08-25 | Essenlix Corporation | COLORIMETRIC TESTS |
| CN110998325B (zh) | 2017-02-09 | 2024-08-16 | 上海宜晟生物科技有限公司 | 扩增测定 |
| US10966634B2 (en) | 2017-02-16 | 2021-04-06 | Essenlix Corporation | Assay with textured surface |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| US11243201B2 (en) | 2017-08-01 | 2022-02-08 | Essenlix Corporation | Sample collection, holding and assaying |
| US11280706B2 (en) | 2017-08-01 | 2022-03-22 | Essenlix Corporation | Dilution calibration |
| CN112689758A (zh) | 2017-08-01 | 2021-04-20 | Essenlix公司 | 检查药物对微生物影响的装置和方法 |
| WO2019075415A1 (en) | 2017-10-13 | 2019-04-18 | Essenlix Corporation | DEVICES AND METHODS FOR AUTHENTICATING MEDICAL ANALYSIS AND USES THEREOF |
| US10807095B2 (en) | 2017-10-26 | 2020-10-20 | Essenlix Corporation | Making and tracking assay card |
| US11237113B2 (en) | 2017-10-26 | 2022-02-01 | Essenlix Corporation | Rapid pH measurement |
| US11609224B2 (en) | 2017-10-26 | 2023-03-21 | Essenlix Corporation | Devices and methods for white blood cell analyses |
| US11648551B2 (en) | 2017-12-12 | 2023-05-16 | Essenlix Corporation | Sample manipulation and assay with rapid temperature change |
| WO2019118936A2 (en) | 2017-12-14 | 2019-06-20 | Essenlix Corporation | Devices, systems, and methods for monitoring hair |
| WO2019140334A1 (en) | 2018-01-11 | 2019-07-18 | Essenlix Corporation | Homogeneous assay (ii) |
| US11885952B2 (en) | 2018-07-30 | 2024-01-30 | Essenlix Corporation | Optics, device, and system for assaying and imaging |
| JP7376040B2 (ja) * | 2019-09-03 | 2023-11-08 | 国立大学法人京都工芸繊維大学 | 神経変性疾患におけるバイオマーカー分子の検出方法 |
| CN115838395A (zh) * | 2022-11-15 | 2023-03-24 | 西北农林科技大学 | 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3601398A1 (de) * | 1986-01-18 | 1987-07-23 | Fresenius Ag | Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen |
| US5133866A (en) * | 1988-03-24 | 1992-07-28 | Terrapin Technologies, Inc. | Method to identify analyte-bending ligands |
| US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| EP0347890B1 (en) * | 1988-06-22 | 1993-03-17 | Roussel Morishita Co., Ltd. | Amino acid nutrient compositions |
| AU6753390A (en) * | 1989-10-02 | 1991-04-28 | University Of Michigan, The | Bioanalytical detection system |
| US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| IL97428A0 (en) | 1990-03-05 | 1992-06-21 | Cephalon Inc | Chymotrypsin-like proteases and their inhibitors |
| US6995141B1 (en) * | 1990-04-04 | 2006-02-07 | Vertex Pharmaceuticals Incorporated | Interleukin 1β protease and interleukin 1β protease inhibitors |
| US5416013A (en) * | 1990-04-04 | 1995-05-16 | Sterling Winthrop Inc. | Interleukin 1β protease and interleukin 1β protease inhibitors |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| GB9024005D0 (en) * | 1990-11-05 | 1990-12-19 | British Bio Technology | Process for amplifying nucleic acid |
| AU675053B2 (en) * | 1991-12-03 | 1997-01-23 | Proteus Molecular Design Limited | Fragments of prion proteins |
| US5312730A (en) * | 1992-05-27 | 1994-05-17 | Ciba Corning Diagnostics Corp. | Immune complex transfer with lypophilic bridge |
| CA2109646C (en) * | 1992-11-24 | 2000-03-07 | Gaston O. Daumy | Para-nitroanilide peptides |
| JPH08178926A (ja) * | 1994-10-25 | 1996-07-12 | Sumitomo Pharmaceut Co Ltd | イムノアッセイプレートおよびその用途 |
| US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
| US5948763A (en) * | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
| US5958684A (en) * | 1995-10-02 | 1999-09-28 | Van Leeuwen; Frederik Willem | Diagnosis of neurodegenerative disease |
| US5750361A (en) | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
| WO1997043649A1 (en) * | 1996-05-14 | 1997-11-20 | Winnacker Ernst Ludwig | CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿ |
| JP2000512131A (ja) * | 1996-05-29 | 2000-09-19 | マクギル ユニバーシティー | プリオン蛋白結合蛋白およびその使用法 |
| US5808011A (en) * | 1996-07-01 | 1998-09-15 | Biopure Corporation | Method for chromatographic removal of prions |
| US6126939A (en) * | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| JPH10182695A (ja) * | 1996-12-27 | 1998-07-07 | Teikoku Seiyaku Co Ltd | ｇｐ１２０に対して親和性を有するペプチド |
| US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
| GB9710582D0 (en) * | 1997-05-22 | 1997-07-16 | Oxford Glycosciences Uk Ltd | A method for de novo peptide sequence determination |
| US6211149B1 (en) * | 1998-08-03 | 2001-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors of formation of protease resistant prion protein |
| US6750025B1 (en) * | 1998-07-09 | 2004-06-15 | V.I. Technologies, Inc. | Method of detecting and isolating prion protein and variants thereof |
| DE19917838A1 (de) * | 1999-01-12 | 2000-07-13 | Bundesrepublik Deutschland Let | Arzneimittel zur prophylaktischen oder therapeutischen Behandlung von transmissiblen spongiformen Enzephalopathien, Morbus Alzheimer und Corea Huntington und anderen neurodegenerativen Erkrankungen sowie diagnostische Mittel |
| DE10027695A1 (de) * | 1999-05-27 | 2001-04-19 | Max Delbrueck Centrum | Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind |
| JP2003521477A (ja) * | 1999-06-23 | 2003-07-15 | カプリオン ファーマシューティカルズ インコーポレーティッド | プリオン蛋白質ペプチドおよびその使用 |
| CA2376914A1 (en) * | 1999-06-29 | 2001-01-04 | Mcgill University | Prion protein binding proteins and uses thereof |
| US6261790B1 (en) * | 1999-07-15 | 2001-07-17 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies |
| EP1204674A4 (en) * | 1999-07-27 | 2005-06-01 | Abgenix Inc | METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS |
| WO2001019867A1 (de) * | 1999-09-14 | 2001-03-22 | Memorec Stoffel Gmbh | Prionen-verwandtes protein |
| US6437102B1 (en) * | 1999-11-24 | 2002-08-20 | Bayer Corporation | Method of separating prions from biological materials |
| WO2001071042A2 (en) * | 2000-03-23 | 2001-09-27 | Pe Corporation (Ny) | Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof |
| EP1272509A2 (en) * | 2000-04-05 | 2003-01-08 | V.I. Technologies, Inc. | Prion-binding peptidic ligands and methods of using same |
| WO2001078344A1 (fr) * | 2000-04-12 | 2001-10-18 | Sony Corporation | Procede et appareil de transmission de donnees |
| GB0009918D0 (en) | 2000-04-20 | 2000-06-07 | Rose Keith | Covalent capture facilitating purification of polypeptides |
| US20020155106A1 (en) * | 2000-12-01 | 2002-10-24 | Hammond David J. | Method of identifying a ligand for a target molecule |
| WO2003016904A2 (en) | 2001-08-13 | 2003-02-27 | Campbell Douglas A | Peptide sequence tags and method of using same |
| DE10152677A1 (de) * | 2001-10-19 | 2003-05-08 | Aventis Behring Gmbh | Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren |
| JP2003149461A (ja) * | 2001-11-12 | 2003-05-21 | Allied Tereshisu Kk | 収納装置 |
| US7863411B2 (en) * | 2002-12-03 | 2011-01-04 | Pathogen Removal and Diagnostics Technologies Inc. | Prion protein ligands and methods of use |
| US7510848B2 (en) * | 2003-04-04 | 2009-03-31 | North Carolina State University | Prion protein binding materials and methods of use |
| DK1615992T3 (da) * | 2003-04-04 | 2013-12-09 | Pathogen Removal & Diagnostic Technologies Inc | Prionproteinbindende materialer og fremgangsmåder til anvendelse |
| WO2006102099A2 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | ANTIBODIES SPECIFIC FOR HUMAN AND BOVINE PrP |
-
2003
- 2003-12-03 US US10/727,335 patent/US7863411B2/en active Active
- 2003-12-03 ES ES10176707.7T patent/ES2531926T3/es not_active Expired - Lifetime
- 2003-12-03 DK DK10176708T patent/DK2312318T3/da active
- 2003-12-03 DK DK08150151T patent/DK1953551T3/da active
- 2003-12-03 CN CN2003801090433A patent/CN1739029B/zh not_active Expired - Lifetime
- 2003-12-03 DK DK03808431.5T patent/DK1573323T3/da active
- 2003-12-03 DK DK10176707T patent/DK2317317T3/da active
- 2003-12-03 EP EP03808431A patent/EP1573323B1/en not_active Expired - Lifetime
- 2003-12-03 PT PT08150151T patent/PT1953551E/pt unknown
- 2003-12-03 EP EP20080150151 patent/EP1953551B1/en not_active Expired - Lifetime
- 2003-12-03 ES ES03808431T patent/ES2375958T3/es not_active Expired - Lifetime
- 2003-12-03 CA CA2836951A patent/CA2836951C/en not_active Expired - Lifetime
- 2003-12-03 AU AU2003302500A patent/AU2003302500B2/en not_active Expired
- 2003-12-03 EP EP20100176707 patent/EP2317317B1/en not_active Expired - Lifetime
- 2003-12-03 CN CN201110113280.3A patent/CN102297798B/zh not_active Expired - Lifetime
- 2003-12-03 JP JP2004557512A patent/JP4485367B2/ja not_active Expired - Lifetime
- 2003-12-03 CN CN2011101132413A patent/CN102241741B/zh not_active Expired - Lifetime
- 2003-12-03 EP EP20100176708 patent/EP2312318B1/en not_active Expired - Lifetime
- 2003-12-03 WO PCT/US2003/038343 patent/WO2004050851A2/en active Application Filing
- 2003-12-03 AT AT03808431T patent/ATE529744T1/de active
- 2003-12-03 MX MXPA05005920A patent/MXPA05005920A/es active IP Right Grant
- 2003-12-03 NZ NZ572892A patent/NZ572892A/en not_active IP Right Cessation
- 2003-12-03 CA CA2507936A patent/CA2507936C/en not_active Expired - Lifetime
- 2003-12-03 NZ NZ560410A patent/NZ560410A/en not_active IP Right Cessation
- 2003-12-03 PT PT10176707T patent/PT2317317E/pt unknown
- 2003-12-03 ES ES10176708.5T patent/ES2527408T3/es not_active Expired - Lifetime
- 2003-12-03 ES ES08150151T patent/ES2460641T3/es not_active Expired - Lifetime
- 2003-12-03 NZ NZ540417A patent/NZ540417A/en not_active IP Right Cessation
- 2003-12-03 PT PT101767085T patent/PT2312318E/pt unknown
- 2003-12-03 PT PT03808431T patent/PT1573323E/pt unknown
-
2005
- 2005-05-31 IL IL168904A patent/IL168904A/en unknown
- 2005-06-02 MX MX2013012129A patent/MX337569B/es unknown
-
2006
- 2006-08-22 HK HK06109265.3A patent/HK1088948A1/xx not_active IP Right Cessation
-
2008
- 2008-02-22 US US12/035,917 patent/US8604161B2/en not_active Expired - Lifetime
-
2009
- 2009-02-05 HK HK09101031A patent/HK1124388A1/xx not_active IP Right Cessation
- 2009-08-18 IL IL200468A patent/IL200468A/en active IP Right Grant
-
2010
- 2010-04-15 AU AU2010201499A patent/AU2010201499B2/en not_active Expired
- 2010-06-01 IL IL206129A patent/IL206129A/en active IP Right Grant
-
2011
- 2011-10-19 HK HK11111159.1A patent/HK1157009A1/xx not_active IP Right Cessation
- 2011-10-19 HK HK11111172.4A patent/HK1157010A1/xx not_active IP Right Cessation
-
2013
- 2013-10-31 US US14/069,052 patent/US9678085B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2312318T3 (da) | Prion-proteinligander samt fremgangsmåder til anvendelse deraf | |
| US20050032138A1 (en) | Method for identifying ligands specific for structural isoforms of proteins | |
| AU2005266208B2 (en) | Substituted triazines as prion protein ligands and their use to detect or remove prions |